Exhibit 10.46
                                SUPPLY AGREEMENT


This  Agreement  is made and entered  into as of the last day signed  below (the
"Effective  Date") by and between  Hollister-Stier  Laboratories  LLC,  having a
principal  place of business at 3525 North Regal  Street,  Spokane,  Washington,
99207-5788   ("Hollister-Stier")  and  Hemispherx  Biopharma,   Inc.,  having  a
principal  place of business at 1716 John F.  Kennedy  Boulevard,  Philadelphia,
Pennsylvania,   19103  ("Hemispherx"  or  "Client").  Both  Hollister-Stier  and
Hemispherx are referred to herein  individually  as "Party" and  collectively as
the "Parties."


                                WITNESSETH THAT:

WHEREAS,  Client has a commercial interest in the manufacture of the Product (as
hereafter   defined)  and  requests  the  services  of  Hollister-Stier  in  the
manufacturing  of the Product  pursuant with the terms and conditions  contained
herein,  and  Hollister-Stier  desires to  manufacture  the Product on behalf of
Client pursuant to the terms and conditions contained herein;

NOW,  THEREFORE,  in  consideration of the premises and the mutual covenants and
agreements contained herein, the Parties agree as follows:


                                    ARTICLE 1
                                   DEFINITIONS

1.       Certain terms are defined in the text of this Agreement.  In addition,
         as used in this Agreement, the following definitions shall apply:

         1.1.     "Act" shall mean the U.S. Food, Drug and Cosmetics Act of 1934
                  (21 U.S. C.ss.301 et seq.) and the regulations promulgated
                  thereunder, as the same may be amended from time to time.

         1.2.     "Polymer I and Polymer C12U" or "Polymer" shall mean the
                  polymer pharmaceutical starting material of the Product
                  further defined in Specifications.

         1.3.     "Affiliate"  shall mean any individual,  firm,  corporation or
                  other legal entity that  directly or indirectly  controls,  is
                  controlled  by, or is under common  control with, a Party.  As
                  used in the preceding  sentence,  "control" means  possession,
                  whether  direct or  indirect,  of the power to direct or cause
                  the direction of the  management  and policies of such entity,
                  whether  pursuant to the  ownership of voting  securities,  by
                  contract or otherwise.

         1.4.     "Batch"  or  "Lot"  shall  mean  each  separate  and  distinct
                  quantity of Product processed under continuous  conditions and
                  designated by Hollister-Stier with a batch or lot number.

         1.5.     "cGMP   Regulations"   means  the   applicable   current  Good
                  Manufacturing Practices as promulgated by the FDA from time to
                  time under the Act, as presently  codified in 21 CFR Parts 210
                  and 211.

         1.6.     "Certificate of Analysis" or "COA" shall mean a document
                  executed by Hollister-Stier to certify
                  that a Batch or Lot of Product meets the Specifications.

         1.7.     "Client's   Technology   Package"  shall  mean  the  technical
                  information  supplied by Client to  Hollister-Stier  to enable
                  Hollister-Stier to carry out its obligations hereunder.  Items
                  in  Client's  Technology  Package  may  include,  but  are not
                  limited  to,  raw   material   and   manufacturing   component
                  specifications,     intermediate    Product    specifications,
                  analytical  and  microbiological  method  validation  reports,
                  analytical  method  transfer   protocols,   filter  validation
                  reports, and storage specifications.

         1.8.     "Confidential    Information"   shall   mean   any   nonpublic
                  information of  Hollister-Stier  or Client  including  without
                  limitation,   trade  secrets,   business  methods,   operating
                  procedures,  manufacturing methods and processes,  prices, and
                  customer  information,  whether of a written,  oral, or visual
                  nature.

         1.9.     "FDA" shall mean the United States Food and Drug
                   Administration.

         1.10.    "Intellectual   Property"  shall  mean  patents,   copyrights,
                  trademarks,  trade names,  service  marks,  licenses and other
                  intellectual property rights of a Party.

         1.11.    "Master Batch Record" shall mean a written  description of the
                  procedure to be followed by Hollister-Stier in processing of a
                  Batch or Lot of Product,  which description shall include, but
                  not be limited to, a complete  list of all active and inactive
                  ingredients,   components,   weights  and  measures   used  in
                  processing  the  Product  within  the  meaning  of 21 CFR part
                  211.186, or its successor as in effect from time to time.

         1.12.    "Product" shall mean the pharmaceutical product described in
                  the Specifications.

         1.13.     "Quality Systems Agreement" shall mean an agreement to be
                   executed by the Parties relating to quality systems.

         1.14.    "Regulatory  Authority" shall mean any federal,  state, local,
                  or international  regulatory  agency,  department,  bureau, or
                  other governmental agency.

         1.15.    "Specifications" shall mean the performance parameters for the
                  Product.  Specifications may be amended from time to time by
                  written agreement of the Parties.

         1.16.    "Third Party" shall mean any party other than Client or
                  Hollister-Stier and their respective Affiliates.

                                    ARTICLE 2
                         REPRESENTATIONS AND WARRANTIES

2.       The Parties agree to the following representations and warranties:

         2.1.     Each Party represents and warrants to the other as follows:

                  2.1.1.   It has full power and authority to enter into this
                           Agreement and perform its obligations hereunder.

                  2.1.2.   Subject to Section 3.2 of this Agreement, it has such
                           permits,  licenses,  and authorizations of Regulatory
                           Authorities,   including,  with  respect  to  Client,
                           Regulatory  Authorities  with  jurisdiction  over the
                           Product,  as  are  necessary  to own  its  respective
                           properties,  conduct  its  business  and  perform its
                           obligations hereunder.

                  2.1.3.   It is not currently debarred, suspended, or otherwise
                           excluded by the FDA or any other Regulatory Authority
                           from conducting  business and shall not knowingly use
                           in connection with this Agreement the services of any
                           person debarred by the FDA.

         2.2.     Hollister-Stier represents and warrants to Client as follows:

                  2.2.1.   Hollister-Stier   shall   process   the   Product  in
                           compliance in all material  respects with the Quality
                           Systems  Agreement,  the Master Batch Record, the Act
                           and the cGMP Regulations.

                  2.2.2.   The  Product  when  delivered  shall  comply  in  all
                           material respects with the Specifications;  provided,
                           however, that Hollister-Stier shall have no liability
                           to Client or any  Third  Party for any  breach of the
                           foregoing  representation  and warranty to the extent
                           that any such breach is caused in whole or in part by
                           Client or by any materials provided by Client.

                  2.2.3.   The  manufacturing  facilities  for the Product shall
                           conform in all material  respects to the standards of
                           those Regulatory  Authorities with  jurisdiction over
                           such facilities, including, but not limited to, those
                           set forth in the cGMP Regulations.

         2.3.     Client represents and warrants to Hollister-Stier as follows:

                  2.3.1.   Neither  Client's  Technology  Package,  nor  the use
                           thereof by Hollister-Stier,  shall infringe,  violate
                           nor misappropriate the rights of any Third Party.

                  2.3.2    Client   has   all   necessary   rights   to   enable
                           Hollister-Stier  to process the Product for Client in
                           accordance  with the  terms  and  conditions  of this
                           Agreement.

                  2.3.3    All laboratory,  scientific,  technical  and/or other
                           data  submitted by or on behalf of Client  (including
                           Client's Technology Package) relating to the Product,
                           to the best of Client's knowledge,  shall be complete
                           and correct and shall not contain any  falsification,
                           misrepresentation or omission.

                  2.3.4.   All materials supplied by or on behalf of Client for
                           use in processing the Product
                           shall conform to the Specifications.

         2.4.     THE  WARRANTIES  SET FORTH  HEREIN ARE THE SOLE AND  EXCLUSIVE
                  WARRANTIES  MADE BY EITHER  PARTY  UNDER THIS  AGREEMENT,  AND
                  NEITHER PARTY MAKES ANY OTHER WARRANTIES EXPRESS OR IMPLIED OR
                  ARISING BY LAW,  INCLUDING,  BUT NOT  LIMITED  TO, ANY IMPLIED
                  WARRANTY  OF  MERCHANTABILITY  OR  FITNESS  FOR  A  PARTICULAR
                  PURPOSE  OR USE OR  ARISING  FROM THE  COURSE OF  PERFORMANCE,
                  COURSE OF DEALING OR USAGE OF TRADE.

         2.5.     EXCEPT AS NECESSARY TO SATISFY A THIRD PARTY CLAIM INDEMNIFIED
                  UNDER ARTICLE 6 OF THIS AGREEMENT, CLIENT'S SOLE AND EXCLUSIVE
                  REMEDY, AND HOLLISTER-STIER'S SOLE AND EXCLUSIVE LIABILITY AND
                  OBLIGATION FOR ANY BREACH OF A REPRESENTATION AND WARRANTY SET
                  FORTH IN SECTION  2.2 SHALL BE FOR  HOLLISTER-STIER  TO PEFORM
                  ITS  OBLIGATIONS  UNDER  SECTIONS 4.1 AND 4.2 OR UNDER SECTION
                  4.4, AS THE CASE MAY BE.

         2.6      EXCEPT AS NECESSARY TO SATISFY A THIRD PARTY CLAIM INDEMNIFIED
                  UNDER  ARTICLE 6 OF THIS  AGREEMENT,  AND/OR IN THE EVENT OF A
                  BREACH OF THE CONFIDENTIALITY OBLIGATIONS SET FORTH IN ARTICLE
                  9 OF THIS AGREEMENT,  UNDER NO CIRCUMSTANCES WILL EITHER PARTY
                  BE LIABLE  TO THE  OTHER  UNDER  ANY  CONTRACT,  TORT,  STRICT
                  LIABILITY,  NEGLIGENCE OR OTHER LEGAL OR EQUITABLE THEORY, FOR
                  THE COST OF COVER OR FOR ANY INDIRECT, INCIDENTAL,  EXEMPLARY,
                  PUNITIVE OR CONSEQUENTIAL  DAMAGES (INCLUDING LOST PROFITS) IN
                  CONNECTION   WITH  THE  SUBJECT  MATTER  OF  THIS   AGREEMENT,
                  INCLUDING,  WITHOUT  LIMITATION,  THE PRODUCT OR ANY  SERVICES
                  PROVIDED IN CONNECTION  WITH THE PRODUCT,  EVEN IF A PARTY HAS
                  BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

         2.7      EXCEPT AS NECESSARY TO SATISFY A THIRD PARTY CLAIM INDEMNIFIED
                  UNDER  ARTICLE 6 OF THIS  AGREEMENT,  AND/OR IN THE EVENT OF A
                  BREACH OF ITS CONFIDENTIALITY OBLIGATIONS SET FORTH IN ARTICLE
                  9  OF   THIS   AGREEMENT,   UNDER   NO   CIRCUMSTANCES   SHALL
                  HOLLISTER-STIER'S TOTAL LIABILITY TO CLIENT IN CONNECTION WITH
                  THE  SUBJECT  MATTER  OF THIS  AGREEMENT,  INCLUDING,  WITHOUT
                  LIMITATION, THE PRODUCT OR ANY SERVICES PROVIDED IN CONNECTION
                  WITH THE  PRODUCT,  EXCEED THE TOTAL  AMOUNT PAID BY CLIENT TO
                  HOLLISTER-STIER UNDER THIS AGREEMENT.

         2.8      NOTHING SET FORTH IN THIS  AGREEMENT  SHALL  RESTRICT OR LIMIT
                  HOLLISTER-STIER'S  RIGHT TO RECOVER DIRECT DAMAGES,  INCLUDING
                  LOST  PROFITS,  FOR ANY BREACH BY CLIENT OF ITS  OBLIGATION TO
                  PAY THE PRICE FOR DELIVERED PRODUCT IN ACCORDANCE WITH ARTICLE
                  3.


                                    ARTICLE 3
    SUPPLY AND PROCESSING OF PRODUCT; FORECASTS, PURCHASE ORDERS AND PAYMENT

3.       The Parties agree to the following supply and processing provisions:

3.1.  Except  as set forth in the  following  sentence,  Client  shall be solely
responsible   for  obtaining  and  maintaining   all  permits,   licenses,   and
authorizations necessary for Hollister-Stier to process, ship and otherwise deal
with  Product.  Hollister-Stier  shall be solely  responsible  for  securing and
maintaining approval of Hollister-Stier's facility as a registered FDA facility.

3.2 Polymer:

3.2.1Client will supply,  at its expense,  sufficient  quantities  of Polymer to
     Hollister-Stier's  facility  prior to the date of delivery set forth in any
     purchase order to enable Hollister-Stier to meet its obligations hereunder.
     All such  Polymer  shall  conform to the  Specifications.  Title to Polymer
     shall  remain at all  times  with  Client.  Except  as  expressly  provided
     otherwise in Sections  3.2.2,  3.2.3 or 3.2.4,  risk of loss of the Polymer
     shall remain at all times with Client.

3.2.2If  Polymer  is  lost  or  damaged  prior  to  processing  as a  result  of
     Hollister-Stier's  negligent acts or omissions,  Hollister-Stier will allow
     Client a purchase price credit for that number of Batches for which Polymer
     was lost or damaged as its sole  liability  and Client's  sole remedy.  For
     example, if Client has provided  Hollister-Stier with sufficient Polymer to
     process  three  Batches,  and  such  Polymer  is lost or  damaged  prior to
     processing as a result of  Hollister-Stier's  negligent  acts or omissions,
     Hollister-Stier  will  process  three  replacement  Batches at no charge to
     Client  (except that Client shall provide  replacement  Polymer at Client's
     expense).

3.2.3If   Polymer   is  lost  or   damaged   in   processing   as  a  result  of
     Hollister-Stier's negligent acts or omissions, Hollister-Stier will replace
     the spoiled  Batch at no charge to the Client  (except  that  Client  shall
     provide replacement Polymer at Client's expense) as Hollister-Stier's  sole
     liability and Client's sole remedy.

3.2.4In the  event  any  loss or  damage  of  Polymer  is  caused  by the  gross
     negligence or willful misconduct of Hollister-Stier,  as  Hollister-Stier's
     sole  liability  and  Client's  sole  remedy  with  respect  to such  gross
     negligence or willful misconduct Hollister-Stier,  at its option, shall (i)
     reimburse  Client for the documented  actual direct  manufacturing  cost to
     Client of the lost or damaged Polymer or (ii) allow Client a purchase price
     credit equal to the documented actual direct  manufacturing  cost to Client
     of the lost or  damaged  Polymer,  up to a maximum  credit of Five  Hundred
     Thousand Dollars  ($500,000),  which purchase price credit shall be applied
     against future purchase orders of the Product.

3.3.   Client  shall  be  responsible   for  release  of  Product  for  sale  or
distribution.

3.4.  Client shall be  responsible  for any  stability  testing  program for the
Product required by the Act and the cGMP Regulations.

3.5. Client shall be responsible  for  maintaining any retention  samples of the
Product required by the Act and the cGMP Regulations.

3.6.  Client  shall  have  the  right,   upon   reasonable   advance  notice  to
Hollister-Stier,   to  conduct  an  annual   audit  to   observe   and   inspect
Hollister-Stier's  facilities and procedures for processing Product. Such annual
inspections  will be made by no more than four (4) Client  representatives,  who
shall execute confidentiality  agreements as requested by Hollister-Stier.  Each
annual  inspection  shall last no more than two (2) business  days.  During such
inspection,   Client's   representatives   shall   (a)  be   accompanied   by  a
representative of Hollister-Stier,  (b) follow such security and facility access
procedures  as are  reasonably  requested by  Hollister-Stier,  and (c) use good
faith efforts to avoid disrupting Hollister-Stier's operations.

3.7   Unless   specifically   requested   otherwise   by  Client   in   writing,
Hollister-Stier will purchase or manufacture reasonable quantities of components
and raw  materials  (other  than  Polymer,  which will be  supplied by Client in
accordance  with Section 3.3),  based on the estimates set forth in the Forecast
(as defined  below).  If the quantity of Product set forth in any purchase order
deviates from the estimate set forth in the immediately preceding Forecast,  and
Hollister-Stier's reliance thereon causes obsolescence of any such components or
raw materials,  Client shall  reimburse  Hollister-Stier  for its  out-of-pocket
costs  incurred in  association  therewith  (including,  but not limited to, any
out-of-pocket  costs related to returning such component or raw materials to the
vendor or otherwise disposing thereof).

3.8. Forecasts, Purchase Orders, Price, Terms of Payment:

3.8.1. Forecasts:  At least 90 days in advance of Client's  first purchase order
     for Product,  Client shall supply  Hollister-Stier with a written,  rolling
     twelve (12) month forecast of Client's  estimated  requirements for Product
     from Hollister-Stier during such 12 month period (the "Forecast"). Every 90
     days thereafter, Client will update and extend the Forecast to cover the 12
     months  beginning  with the date of such updated  Forecast.  Each  Forecast
     shall include an estimated  number of Batches and requested  delivery dates
     for the 12 months covered by such Forecast. Amounts set forth in a Forecast
     are estimates,  to be used for planning  purposes only, and Forecasts shall
     not constitute purchase orders.

3.8.2. Purchase Orders: Client will provide Hollister-Stier with a firm purchase
     order  at  least  sixty  (60)  days  prior to the  earliest  delivery  date
     specified  in such  purchase  order.  All  purchase  orders will be sent by
     facsimile or electronic mail to the address specified by Hollister-Stier.

3.8.2.1. Each purchase order and any acknowledgment thereof shall be governed by
     the terms of this  Agreement.  In the event a Party uses forms or documents
     to place or accept  purchase  orders that contain terms and conditions that
     are in  addition to or  contrary  to those in this  Agreement,  the Parties
     agree  and  acknowledge  that  such  forms  or  documents  will be used for
     convenience only, and that no terms or conditions set forth therein, except
     with respect to quantity, shall be of any force or effect.  Hollister-Stier
     shall be deemed to have accepted a purchase  order unless it objects within
     ten business days after receiving a purchase  order.  If  Hollister-Stier's
     objection  is based on its belief that it cannot  accommodate  the delivery
     date  requested  in the  purchase  order then the Parties  will agree on an
     alternative delivery schedule.  If Hollister-Stier's  objection is based on
     Hollister-Stier's  inability to supply the quantity of Product set forth in
     the purchase order,  Client may cancel the purchase order without  penalty,
     payment  or  consequence.  Once a  purchase  order is  accepted  or  deemed
     accepted  by  Hollister-Stier,  Hollister-Stier  will  be  required  to use
     commercially  reasonable  efforts to produce  the  quantity  of Product set
     forth in the purchase  order for delivery on the dates(s) set forth in such
     purchase order.

3.8.2.2.  Client  reserves the right to cancel or postpone  any  purchase  order
     after  acceptance  by  Hollister-Stier.  However,  should  Client cancel or
     postpone any purchase order within fourteen (14) calendar days prior to the
     scheduled  delivery date,  Client shall pay  Hollister-Stier a cancellation
     fee  equivalent to 50% of the purchase  price for the Product  described in
     the purchase order.

3.8.3. Price and Shipping:  Client shall pay  Hollister-Stier,  in U.S. dollars,
     the price per quotation 576-2-9-0 attached as Exhibit A annexed hereto. The
     price excludes all taxes, duties,  shipping,  insurance and other expenses.
     Beginning  on the first  anniversary  of the  Effective  Date,  and on each
     succeeding  anniversary  of the  Effective  Date  during  the  term of this
     Agreement,  the  then  current  price  shall  be  increased  by the  annual
     percentage  increase,  if any, for the most recent twelve (12) month period
     for  which  figures  are   available  in  the   "Producer   Price  Index  -
     Pharmaceutical  Preparations"  (code PCU2834) (the "PPI")  published by the
     U.S.  Bureau of Labor  Statistics  (the "BLS") or, if the same is no longer
     published,  the successor  index  published by the BLS that is most similar
     thereto.  If the PPI is discontinued  and not replaced with a corresponding
     or similar  index,  then the Parties  shall,  in good  faith,  agree upon a
     replacement  PPI. Price  increases  shall be effective for all new purchase
     orders placed after the applicable anniversary.  Product shall be delivered
     FOB Hollister-Stier's facility, Spokane, Washington, either freight collect
     or  freight  prepaid,   and  Hollister-Stier   will  ship  Product  to  the
     destination,  and via the  carrier,  that Client  specifies in the purchase
     order.  Risk of loss shall pass to Client  when the  Product is tendered to
     the  carrier for  shipment.  Shipment  and  insurance  of Product  shall be
     arranged by Client and the price and  liability of such  shipment  shall be
     borne by Client.

3.8.4. Terms of Payment:  Invoices  shall be payable to  Hollister-Stier  within
     thirty (30) calendar days after Client's acceptance or deemed acceptance of
     Product as set forth in Article 4. All amounts not paid when due shall bear
     interest from the due date at the rate of one and one-half  percent  (1.5%)
     per month.

3.8.4.1. Invoices shall be sent to the following address:

                                       Hemispherx BioPharma, Inc.
                                       Attention:  Accounts Payable
                                       1716 John F. Kennedy Boulevard
                                       Philadelphia, PA  19103

3.8.4.2. All payments due  hereunder  to  Hollister-Stier  shall be sent by wire
     transfer of funds via the Federal Reserve Wire Transfer System to:

                                   Wells Fargo Bank
                                   ABA# 121000248
                                   Beneficiary:Hollister-Stier Laboratories LLC
                                   Account # 4131352601
                                   Swift Code WFBIUS4S

                                   Or by mail to:
                                   Hollister-Stier Laboratories LLC
                                   P.O. Box 201236
                                   Dallas, TX  75320-1236

3.9. Right of First Refusal to Manufacture:

                  In  the  event  Client   makes  any  material   modifications,
                  enhancements,  or improvements  to the Product,  or develops a
                  derivative  thereof,  Client shall notify  Hollister-Stier and
                  provide  Hollister-Stier  with a  written  description  of the
                  proposed specifications for such modified, enhanced, improved,
                  derived or new Product (the "Descriptive  Notice"), as well as
                  any related  information which may be reasonably  requested by
                  Hollister-Stier  within  ten  (10)  days of  Hollister-Stier's
                  receipt of the Descriptive Notice.  Hollister-Stier shall have
                  thirty (30) days following the receipt of such  information in
                  which to agree with  Client  upon  satisfactory  terms for the
                  price and terms for the  manufacture  of such  Product  before
                  Client may begin  negotiations  with any Third Party regarding
                  such manufacture.




                                    ARTICLE 4
              INSPECTION AND REJECTION OF PRODUCT; QUALITY CONTROL

4. The Parties agree to the following  provisions for acceptance or rejection of
Product and certain matters relating to quality control:

4.1. Each Batch of Product delivered to Client hereunder shall be accompanied by
     a Certificate of Analysis  signed by a duly  authorized  representative  of
     Hollister-Stier.  Client  shall  have 30 days from the date of  receipt  of
     Product  to   inspect   and  reject   acceptance   by  written   notice  to
     Hollister-Stier;  provided,  however,  that any such notice shall set forth
     Client's reasons for rejection in reasonable detail and provided,  further,
     that Client may reject Product only if: (i) Client claims a material breach
     of Hollister-Stier's  representations and warranties in Section 2.2 of this
     Agreement with respect to such Product; or (ii)  Hollister-Stier has failed
     to deliver a Certificate of Analysis for such Product.  If  Hollister-Stier
     does not receive  Client's  written notice of rejection  within such 30 day
     period, Client shall be deemed to have accepted Product.

4.2  In the  event  Client  provides  Hollister-Stier  with a timely  notice  of
     rejection  as set forth in Section  4.1,  Client  shall return the rejected
     Product to Hollister-Stier at  Hollister-Stier's  expense.  Hollister-Stier
     shall have 30 days following  receipt of rejected  Product in which to test
     such   Product.   If   Hollister-Stier   does  not  dispute  a   rejection,
     Hollister-Stier  shall rework or replace the rejected Product promptly,  at
     Hollister-Stier's  expense (except for replacement  Polymer,  which will be
     provided by Client at  Client's  expense)  and such  rework or  replacement
     shall  constitute  Client's  exclusive  remedy and  Hollister-Stier's  sole
     liability  with respect to such rejection  (unless  Sections 3.3.3 or 3.3.4
     apply, in which case,  Client shall have the remedy set forth therein).  If
     Hollister-Stier disputes a rejection,  Hollister-Stier shall provide Client
     with written  notice of such  dispute  within 30 days after  receiving  the
     returned Product, and the Parties shall use commercially reasonable efforts
     to resolve the dispute amicably and promptly.  If the Parties are unable to
     reach a resolution  within 30 days after Client's notice of rejection,  the
     returned  Product  shall be  submitted  to any  independent  laboratory  or
     consultant  mutually  acceptable to the Parties,  whose  decision as to the
     conformity  of such  Product  with the  Specifications  shall be final  and
     binding.  The Party  against  whom the  dispute  is  decided  shall pay any
     charges for such laboratory or consultant.  If the laboratory or consultant
     determines that the returned Product did not conform to the Specifications,
     Hollister-Stier  shall replace the rejected  Product at no charge to Client
     (except that Client shall provide replacement Polymer at Client's expense),
     and  such  replacement  shall  constitute  Client's  exclusive  remedy  and
     Hollister-Stier's  sole  liability  with respect to such  rejected  Product
     (unless Sections 3.3.3 or 3.3.4 apply, in which case, Client shall have the
     remedy set forth therein).

4.3  In addition  to any safety  requirements  set forth in the Quality  Systems
     Agreement or the Master Batch Record,  Hollister-Stier shall develop, adopt
     and enforce safety  procedures for processing  Product in compliance in all
     material  respects with the Act and the cGMP  Regulations.  Hollister-Stier
     shall be responsible for treating and/or disposing,  in compliance with the
     Act and the cGMP Regulations in all material respects,  all waste generated
     as a  result  of such  processing,  and for  maintaining  required  records
     related thereto.

4.4  In the event (a) any Regulatory  Authority  issues a request,  directive or
     order that any of the Product be recalled,  withdrawn, or corrected,  (b) a
     court of competent  jurisdiction orders such an action, or (c) either Party
     reasonably  determines  that any Product  should be recalled,  withdrawn or
     corrected,  the Parties shall take all  appropriate  corrective  actions as
     they reasonably mutually determine, and shall cooperate in any governmental
     investigations  relating to the  Product.  As between  Hollister-Stier  and
     Client, Client shall be solely responsible for initiating,  conducting, and
     managing  any recall,  withdrawal  or  correction  effort.  Client shall be
     solely  responsible for all related expenses,  except that  Hollister-Stier
     shall be liable for such expenses to the extent that the recall, withdrawal
     or correction  resulted solely from a breach by  Hollister-Stier  of any of
     its  representation  and  warranties  set  forth  in  Section  2.2 of  this
     Agreement.

4.5  Client shall provide to Hollister-Stier  copies of all material  regulatory
     submissions that relate to Hollister-Stier's services under this Agreement,
     which  copies  shall be  provided  reasonably  in  advance  of  submission.
     Hollister-Stier  shall consult with Client in responding to questions  from
     the Regulatory  Authorities regarding processing of the Product. Each Party
     shall  notify  the  other  promptly  after  receipt  of any  notice  of any
     Regulatory Authority  inspection,  investigation or other inquiry involving
     the Product.  The Parties shall  cooperate  with each other during any such
     inspection,  investigation or other inquiry including,  but not limited to,
     allowing,  upon  reasonable  request,  a  representative  of the  other  to
     participate  during such inspection,  investigation  or other inquiry,  and
     providing copies of all relevant documents.

4.6. The Parties agree to the following  provisions regarding adverse events and
     complaints:

                  4.6.1    Client  shall be  responsible  to (a) report  adverse
                           events  involving  the  Product  to the FDA and other
                           Regulatory  Authorities,  and (b)  respond to quality
                           complaints  and  medical  and  technical   inquiries,
                           respecting the Product.

                  4.6.2    In the event Hollister-Stier (a) receives information
                           regarding any adverse event
                           relating to the Product, (b) receives any complaints
                           relating to the Product, (c)
                           receives any medical or technical inquiry relating to
                           the Product, or (d) discovers or
                           is notified of any material defect in the Product, it
                           shall (i) promptly notify Client
                           and (ii) conduct an investigation in accordance with
                           its normal procedures for
                           complaints, inquiries or discoveries of that nature
                           and promptly report the results of
                           such investigation to Client.  The Parties shall
                           reasonably cooperate with and assist
                           each other, at Client's cost, in connection with any
                           such matter.


                                    ARTICLE 5
                          INTELLECTUAL PROPERTY RIGHTS

536:  5.The Parties agree to the following provisions regarding Intellectual
     Property:

         5.1      License  Grant:   Client  hereby  grants   Hollister-Stier   a
                  nonexclusive,  United States,  royalty-free license during the
                  term of this Agreement to use Client's  Technology Package and
                  Client's  Intellectual  Property  rights in the performance of
                  Hollister-Stier's obligations under this Agreement.

         5.2.     Limitation  of  Use:  Except  as  expressly   stated  in  this
                  Agreement,  no  Intellectual  Property  rights  of any kind or
                  nature are conveyed by this  Agreement and except as set forth
                  in Section 5.1,  neither Party shall have any right,  title or
                  interest  in or to the  other  Party's  Intellectual  Property
                  rights for any purpose  whatsoever  without such other Party's
                  prior written consent.  Upon termination of this Agreement for
                  whatever  reason,  neither  party  shall use or exploit in any
                  manner  whatsoever  any  Intellectual  Property  rights of the
                  other Party.


                                    ARTICLE 6
                     INDEMNIFICATION FOR THIRD PARTY CLAIMS

6. The Parties  agree to the following  clauses  regarding  indemnification  for
Third Party claims:

         6.1.     Indemnification by Client:  Client shall indemnify, defend and
                  hold Hollister-Stier, its
                  Affiliates and their respective directors, officers,employees,
                  agents, successors and assigns
                  harmless from and against any damages, losses, judgments,
                  claims, suits, actions, liabilities,
                  costs and expenses (including, but not limited to, reasonable
                  attorneys' fees) (collectively,
                  "Liabilities") resulting from any Third Party claims or suits
                  arising out of (1) the ownership,
                  use, handling, distribution, marketing or sale of the Product,
                  (2) Client's breach of any of
                  its warranties or representations, or failure to perform any
                  of its obligations, hereunder, or
                  (3) Client's negligent acts or omissions or willful
                          misconduct.

         6.2.     Indemnification  by  Hollister-Stier:   Hollister-Stier  shall
                  indemnify,  defend and hold Client,  its  Affiliates and their
                  respective directors,  officers, employees, agents, successors
                  and  assigns   harmless  from  and  against  any   Liabilities
                  resulting  from any  Third  Party  claims  arising  out of (1)
                  Hollister-Stier's  services in  manufacturing,  processing  or
                  assembling the Product,(2)  Hollister-Stier's breach of any of
                  its warranties or  representations,  or failure to perform any
                  of  its  obligations,   hereunder  or  (3)   Hollister-Stier's
                  negligent acts or omissions or willful misconduct.

         6.3.     Indemnification Procedures:

                  6.3.1.   Any Party hereto  seeking  indemnification  hereunder
                           (in  this  context  the  "Indemnified  Party")  shall
                           notify  the  other   Party  (in  this   context   the
                           "Indemnifying  Party") in writing reasonably promptly
                           after the assertion against the Indemnified Party any
                           claim by a Third  Party (a "Third  Party  Claim")  in
                           respect  of which the  Indemnified  Party  intends to
                           base a claim for indemnification hereunder.

                  6.3.2.   (1) The Indemnifying Party shall have the right, upon
                           written notice given to the Indemnified  Party within
                           thirty (30) calendar days after receipt of the notice
                           from the Indemnified  Party of any Third Party Claim,
                           to assume  the  defense  and  handling  of such Third
                           Party  Claim,  at  the   Indemnifying   Party's  sole
                           expense,  in which  case the  provisions  of  Section
                           6.3.2(2) below shall govern.

                           (2)  The  Indemnifying  Party  shall  select  counsel
                           reasonably  acceptable  to the  Indemnified  Party in
                           connection  with  conducting the defense and handling
                           of such Third Party Claim, and the Indemnifying Party
                           shall defend or handle the same in consultation  with
                           the Indemnified Party, and shall keep the Indemnified
                           Party  appraised  of the  status of the  Third  Party
                           Claim. The Indemnifying  Party shall not, without the
                           prior written consent of the Indemnified Party, which
                           consent will not be unreasonably withheld, agree to a
                           settlement  of  any  Third  Party  Claim  that  could
                           directly or  indirectly  lead to  liability or create
                           any financial or other  obligation on the part of the
                           Indemnified  Party for which the Indemnified Party is
                           not  entitled  to  indemnification   hereunder.   The
                           Indemnified    Party   shall   cooperate   with   the
                           Indemnifying   Party   and  shall  be   entitled   to
                           participate  in the defense or handling of such Third
                           Party Claim with its own counsel at its own expense.

                  6.3.3.   (1) If the  Indemnifying  Party does not give written
                           notice to the Indemnified  Party,  within thirty (30)
                           calendar  days after  receipt of the notice  from the
                           Indemnified  Party of any Third Party  Claim,  of the
                           Indemnifying  Party's  election to assume the defense
                           or handling of such Third Party Claim, the provisions
                           of Section 6.3.3(2) below shall govern.

                           (2) The  Indemnified  Party may, at the  Indemnifying
                           Party's  expense,  select counsel in connection  with
                           conducting  the  defense  or  handling  of such Third
                           Party  Claim and defend or handle  such  Third  Party
                           Claim  in such  manner  as it may  deem  appropriate,
                           provided,  however,  that the Indemnified Party shall
                           keep the  Indemnifying  Party timely appraised of the
                           status of such Third Party Claim and shall not settle
                           such Third  Party  Claim  without  the prior  written
                           consent  of the  Indemnifying  Party,  which  consent
                           shall   not   be   unreasonably   withheld.   If  the
                           Indemnified Party defends or handles such Third Party
                           Claim,  the  Indemnifying  Party shall cooperate with
                           the  Indemnified  Party  and  shall  be  entitled  to
                           participate  in the defense or handling of such Third
                           Party  Claim  with  its  own  counsel  and at its own
                           expense.

                  6.3.4.   The indemnification remedies in this Article 6, shall
                           constitute  the sole and  exclusive  remedies  of the
                           Parties  with  respect  to  any  Third  Party  Claims
                           arising under or relating to this Agreement.

         6.4.     Limitation of Liability:  Notwithstanding any other provisions
                  of this Agreement, Hollister-Stier's aggregate indemnification
                  liability to Client and its  Affiliates for Third Party Claims
                  pursuant  to this  Article 6 shall  not  exceed  Five  Million
                  United States Dollars (US $5,000,000).



                                    ARTICLE 7
                                    INSURANCE

         Each of Client and  Hollister-Stier  shall obtain and maintain,  either
         itself  or  through  one or  more  of its  Affiliates,  with  reputable
         carriers,  product liability insurance with limits of not less than One
         Million  United States  Dollars (US  $1,000,000)  per claim,  and Three
         Million United States Dollars (US  $3,000,000)  annual  aggregate by no
         later than the  scheduled  delivery date for the first Batch of Product
         delivered under this Agreement.  Upon request, each Party shall furnish
         the other Party with a certificate  that such insurance is in force. In
         the  event  of any  proposed  cancellation,  non-renewal,  or  material
         adverse change in such coverage,  the other Party hereto shall be given
         at least thirty (30) calendar day's advance written notice thereof.


                                    ARTICLE 8
                              TERM AND TERMINATION

8. The Parties agree to the following clauses regarding the term and termination
of this Agreement:

8.1. Term:  This Agreement shall remain in full force and effect for a period of
five years.

8.2.  Termination for Default:  This Agreement may be terminated by either Party
in the event of  material  breach or default by the other Party of the terms and
conditions hereof;  provided,  however,  the other Party shall first give to the
defaulting  Party written notice of the proposed  termination or cancellation of
this Agreement,  specifying the grounds  therefor.  Upon receipt of such notice,
with  respect to such  defaults as are capable of being  cured,  the  defaulting
Party shall have sixty (60) calendar days to respond by curing such default.  If
the  breaching  Party does not respond or fails to work  diligently  and to cure
such  breach  within  such  sixty  (60) day  period,  then the  other  Party may
terminate this Agreement.

8.3. Bankruptcy or Insolvency:

                  8.3.1.   Either Party may terminate this Agreement upon the
                           occurrence of any of the following
                           with respect to the other Party:

                           8.3.1.1.    The filing of an involuntary petition
                                       under the U.S. Bankruptcy Code, or
                                       any other similar law, which is not
                                       dismissed within sixty (60) days after
                                       the filing date;

                           8.3.1.2.    The filing of a voluntary petition by
                                       such other Party for relief under
                                       the U.S. Bankruptcy Code or other similar
                                       law; or

                           8.3.1.3.    The failure of such other Party to pay
                                       its debts when they become due.

8.4. Rights and Duties Upon Termination:

                  Termination of this Agreement for whatever  reason,  shall not
                  affect the obligations of either Party,  including  payment of
                  obligations which have accrued prior to such termination. Upon
                  termination  of this  Agreement,  other than due to an uncured
                  breach of this  Agreement  by  Hollister-Stier,  Client  shall
                  purchase from  Hollister-Stier,  at the out-of-pocket  cost to
                  Hollister-Stier,  any components  and raw materials  purchased
                  for the Product which Hollister-Stier has purchased based upon
                  any Forecast.  Hollister-Stier  shall ship such components and
                  raw materials to Client at Client's  expense and in accordance
                  with  Client's  instructions  promptly  after  receiving  such
                  payment.  Articles  1 and  2,  Sections  3.9.3  and  8.4,  and
                  Articles 6, 9, 10, 11 and 12 , and all other  provisions  that
                  may  reasonably be construed as surviving the  termination  of
                  this Agreement shall survive the termination.

                                    ARTICLE 9
                                 CONFIDENTIALITY

9.       In carrying out their respective  obligations under this Agreement,  it
         is recognized by  Hollister-Stier  and Client that each may disclose to
         the other  Confidential  Information of the disclosing  Party, and they
         hereby agree as follows with respect to any such disclosure:

         9.1.     Form of Disclosure: Confidential Information may be disclosed
                  in oral, written or electronic form.

         9.2.     Obligations:  The  receiving  Party  shall  hold  Confidential
                  Information  in confidence  and use it only for the purpose of
                  performing its  obligations  under this  Agreement.  Except as
                  provided  below,  the  receiving  Party  shall  not  disclose,
                  disseminate or distribute any such Confidential Information to
                  any Third Party unless prior  written  authorization  has been
                  obtained from the disclosing  Party.  These  obligations shall
                  not apply to:

                  9.2.1.   Information which, at the time of disclosure, is
                           generally known to the public;

                  9.2.2.   Information which, after disclosure, becomes
                           generally known to the public by
                           publication or otherwise, except by breach of this
                           Agreement by the receiving Party;

                  9.2.3.   Information which the receiving Party can demonstrate
                           by its written  records was in the receiving  Party's
                           possession at the time of the  disclosure,  and which
                           was not  acquired  directly or  indirectly,  from the
                           disclosing    Party    under   an    obligation    of
                           confidentiality;

                  9.2.4.   Information which is lawfully disclosed to the
                           receiving Party on a non-confidential
                           basis by a Third Party who is not obligated to the
                           disclosing Party or any other Third
                           Party to retain such information in confidence;

                  9.2.5.   Information which results from independent research
                           and development by the receiving
                           Party, as shown by competent evidence; or

                  9.2.6.   Information  which is  required  to be  disclosed  by
                           legal process;  provided that the Party so disclosing
                           such  Confidential  Information  timely  informs  the
                           other Party and uses commercially  reasonable efforts
                           to limit the disclosure, maintain its confidentiality
                           to the extent possible, and permit the other Party to
                           attempt  by  appropriate  legal  means to limit  such
                           disclosure.

         9.3.     Each Party covenants and agrees that it has and shall use
                  commercially reasonable efforts to
                  prevent the unauthorized use, disclosure, copying,
                  dissemination or distribution of
                  Confidential Information.  Without limiting the foregoing,
                  the receiving Party shall make
                  Confidential Information of the other Party available only
                  to those of its employees, agents
                  and other representatives who have a need to know the same
                  for the purpose carrying out this
                  Agreement, who have been informed that the Confidential
                  Information belongs to the disclosing
                  Party and is subject to this Agreement, and who have agreed
                  or are otherwise obligated to
                  comply with the confidentiality provisions of this Agreement.


                                   ARTICLE 10
                        FORCE MAJEURE/DISPUTE RESOLUTION

10.      The Parties agree to the following:

     10.1.Effect  of  Force  Majeure:  Neither  Party  shall be held  liable  or
          responsible  for any loss or  damages  resulting  from any  failure or
          delay in its performance  due hereunder  (other than payment of money)
          caused by force majeure. As used herein, force majeure shall be deemed
          to include any condition beyond the reasonable control of the affected
          Party including, without limitation,  strikes or other labor disputes,
          war,  riot,  earthquake,  tornado,  hurricane,  flood or other natural
          disasters, fire, civil disorder,  explosion,  accident, sabotage, lack
          of or inability to obtain  adequate  fuel,  power,  materials,  labor,
          containers,  transportation,  supplies or equipment,  compliance  with
          governmental requests,  laws, rules,  regulations,  orders or actions;
          inability  despite good faith  efforts to renew  operating  permits or
          licenses  from  local,  state  or  federal  governmental  authorities;
          breakage  or failure  of  machinery  or  apparatus;  national  defense
          requirements; or supplier strike, lockout or injunction.

     10.2.Notice of Force  Majeure:  In the event  either  Party is  delayed  or
          rendered  unable to perform due to force  majeure,  the affected Party
          shall give notice of the same and its  expected  duration to the other
          Party promptly after the occurrence of the cause relied upon, and upon
          the giving of such  notice  the  obligations  of the Party  giving the
          notice will be suspended  during the continuance of the force majeure;
          provided, however, such Party shall take commercially reasonable steps
          to remedy or mitigate the force majeure with all reasonable  dispatch.
          The  requirement  that force majeure be remedied  with all  reasonable
          dispatch  shall  not  require  the  settlement  of  strikes  or  labor
          controversies by acceding to the demands of the opposing party.

     10.3.Dispute  Resolution:  The Parties hereto agree to perform the terms of
          this  Agreement  in  good  faith,   and  to  attempt  to  resolve  any
          controversy,  dispute or claim  arising  hereunder in good faith.  Any
          dispute  regarding  the  validity,  construction,  interpretation,  or
          performance of this Agreement (other than provisions,  hereof relating
          to  any   Intellectual   Property  rights,   or  the   confidentiality
          obligations  contained  in  Article  9  hereof)  shall  be  (1)  first
          attempted to be resolved  between the  CEO/President of each Party and
          failing  that  (2)  submitted  to  binding   arbitration  in  Spokane,
          Washington,  U.S.A. to be conducted in accordance with the Arbitration
          Rules of the American Arbitration Association; provided, however, that
          nothing in this Section  10.3 shall be  construed  to preclude  either
          Party from seeking provisional  remedies,  including,  but not limited
          to, temporary restraining orders and preliminary injunctions, from any
          court  of  competent  jurisdiction,  in order to  protect  its  rights
          pending  arbitration,  but such preliminary relief shall not be sought
          as a means of avoiding arbitration. Further, in the event of a dispute
          under   Section  4.2,  the  Parties  shall  comply  with  the  dispute
          resolution   provisions  set  forth  in  Article  4.  Any  arbitration
          hereunder  shall be submitted to an  arbitration  tribunal  made up of
          three (3)  members,  one of whom shall be selected  by Client,  one of
          whom shall be  selected by  Hollister-Stier,  and one of whom shall be
          selected by the other two arbitrators.  The third arbitrator  selected
          by the first two shall chair the panel.  All  arbitration  proceedings
          shall be conducted in English.  The order or award of the  arbitrators
          shall be reasoned  and shall be final and may be enforced in any court
          of competent jurisdiction. The substantially prevailing Party shall be
          entitled, in addition to any other rights and remedies it may have, to
          reimbursement for its expenses incurred thereby,  including court cost
          and reasonable attorneys' fees, from the substantially  non-prevailing
          Party.


                                   ARTICLE 11
                                     NOTICES

                  Except as otherwise  specifically  set forth in Section  3.9.2
                  with  respect  to  purchase  orders,  all  notices  and  other
                  communications  provided  herein shall be in writing and shall
                  be deemed to be delivered  when deposited in the United States
                  mail,  postage prepaid and certified,  or  hand-delivered,  or
                  sent  by  facsimile,  or  express  service  courier,   charges
                  prepaid, to the address of the other Party designated below:

-------------------------------------   --------------------------------------

             Client                                Hollister-Stier

   Hemispherx Biopharma, Inc.               Hollister-Stier Laboratories LLC
 1716 John F. Kennedy Boulevard                3525 North Regal Street
    Philadelphia, PA 19103                        Spokane, WA 99207
 Attention: William A. Carter, M.D.      Attention: Anthony D. Bonanzino, Ph.D.
                                                 FAX: (509) 482-3543

-------------------------------------  ---------------------------------------

         The addresses and persons provided above may be changed by either Party
         by providing the other Party with written notice of such change.


                                   ARTICLE 12
                                  MISCELLANEOUS

12.      The Parties agree to the following miscellaneous clauses:

         12.1.    Entire Agreement:  This Agreement and attached exhibit
                  contains the entire understanding
                  between the Parties with respect to the subject matter hereof,
                  and may be modified only by a
                  written instrument duly executed by each Party's authorized
                  representative.

         12.2.    Independent   Contractors:   The   Parties   are   independent
                  contractors  and nothing  contained in this Agreement shall be
                  construed  to  place  them in the  relationship  of  partners,
                  principal  and agent,  employer/employee  or joint  venturers.
                  Neither  Party  shall have power or right to bind or  obligate
                  the other, nor hold itself out as having such authority.

         12.3.    Publicity:  Except as  explicitly  set forth  below in Section
                  12.4,  any press  release,  publicity  or other form of public
                  written  disclosure  related to this Agreement prepared by one
                  Party shall be  submitted  to the other party prior to release
                  for written approval, which approval shall not be unreasonably
                  withheld or delayed by such other Party.

         12.4.    Use of Party's Name:  Except as expressly provided or
                  contemplated hereunder and except as
                  otherwise required by applicable law, no right is granted
                  pursuant to this Agreement to either
                  Party to use in any manner the trademarks or name of the other
                  Party, or any other trade name,
                  service mark, or trademark owned by or licensed to the other
                  Party in connection with the
                  performance of the Agreement.  To the extent required by
                  applicable law, the Parties shall be
                  permitted to use the other Party's name and disclose the
                  existence and terms of this Agreement
                  in connection with required public regulatory filings, public
                  securities filings and private
                  placement memoranda and documentation, using reasonable
                  commercial efforts to protect the
                  confidentiality of the terms of this Agreement.

         12.5.    Severability:  If  any  provision  of  this  Agreement  or any
                  Exhibit is held to be invalid or  unenforceable to any extent,
                  then (a) such  provision  shall be  interpreted,  construed or
                  reformed to the extent reasonably required to render it valid,
                  enforceable and consistent  with the Parties'  original intent
                  underlying   such   provision  and  (b)  such   invalidity  or
                  unenforceability  shall not affect any other provision of this
                  Agreement or any other agreement between the Parties.

         12.6.    Assignment:  This Agreement may not be assigned or otherwise
                  transferred by either Party
                  without the prior written consent of the other Party;provided,
                  however, either Party may,
                  without such consent, assign this Agreement

                  (a)      in connection with the transfer or sale of all or
                           substantially all of the assets of
                           such Party or the line of business of which this
                           Agreement forms a part, or

                  (b)      in the event of a merger or consolidation of a Party.

                  Any purported  assignment in violation of the preceding  shall
                  be void. Any permitted  assignee shall assume all  obligations
                  of its assignor  under this  Agreement.  No  assignment  shall
                  relieve either Party of responsibility  for the performance of
                  any  obligation  which accrued prior to the effective  date of
                  such assignment.

         12.7.    Governing  Law:  This  Agreement  shall  be  governed  by  and
                  construed  in  accordance  with  the  laws  of  the  state  of
                  Washington,  irrespective  of any  conflicts of law rule which
                  may direct or refer such  determination  of applicable  law to
                  any other state,  and if this Agreement were performed  wholly
                  within the state of Washington.

         12.8.    Headings:  Paragraph headings and captions used herein are for
                  convenience of reference only
                  and shall not be used in the construction or interpretation
                  of this Agreement.

         12.9.    Waiver:  Neither  Party's  waiver of any  breach or failure to
                  enforce any of the terms and  conditions of this  Agreement at
                  any time, shall in any way affect, limit or waive such Party's
                  right thereafter to enforce and compel strict  compliance with
                  every term and  condition of this  Agreement.  Any such waiver
                  shall be made in writing.

         12.10.   Construction:  This Agreement has been jointly prepared on
                  the basis of the mutual
                  understanding of the Parties and shall not be construed
                  against either Party by reason of such
                  Party's being the drafter hereof or thereof.

         12.11.   Exhibits:  Any and all exhibits referred to herein form an
                  integral part of this Agreement and
                  are incorporated into this Agreement by this reference.

         12.12    Counterparts:  This Agreement may be executed in counterparts,
                  each of which  shall be deemed an  original  and both of which
                  together shall constitute a single instrument.





IN WITNESS  WHEREOF,  this  Agreement has been executed by the Parties as of the
Effective Date.


FOR: HOLLISTER-STIER LABORATORIES LLC      FOR:  HEMISPHERX BIOPHARMA, INC.

/s/                                          /s/
----------------------------               -----------------------
Signature                                  Signature


Anthony D. Bonanzino, Ph. D.               William A. Carter, M.D.
----------------------------               -----------------------
Printed Name                               Printed Name


President and CEO                          Chairman and CEO
----------------------------               -----------------------
Title                                      Title


----------------------------               -----------------------
Date Signed                                Date Signed





<PAGE>



                                    EXHIBIT A

                               QUOTATION 576-2-9-0